Regeneron Pharmaceuticals (REGN) Stock Forecast, Price Target & Predictions
REGN Stock Forecast
Regeneron Pharmaceuticals stock forecast is as follows: an average price target of $995.63 (represents a 31.56% upside from REGN’s last price of $756.81) and a rating consensus of 'Buy', based on 26 wall street analysts offering a 1-year stock forecast.
REGN Price Target
The average price target for Regeneron Pharmaceuticals (REGN) is $995.63 based on 1-year price targets from 26 Wall Street analysts in the past 3 months, with a price target range of $1.29K to $604.00. This represents a potential 31.56% upside from REGN's last price of $756.81.
REGN Analyst Ratings
According to 26 Wall Street analysts, Regeneron Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for REGN stock is 0 'Strong Buy' (0.00%), 22 'Buy' (84.62%), 4 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Regeneron Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 01, 2024 | Evan David Seigerman | BMO Capital | $1.19K | $843.60 | 41.06% | 57.24% |
| Nov 01, 2024 | Christopher Raymond | Piper Sandler | $1.20K | $843.60 | 41.65% | 57.90% |
| Nov 01, 2024 | Andrew Berens | Leerink Partners | $880.00 | $843.60 | 4.31% | 16.28% |
| Oct 31, 2024 | Cory Kasimov | Evercore ISI | $1.17K | $838.20 | 39.58% | 54.60% |
| Oct 24, 2024 | Cory Kasimov | Evercore ISI | $1.18K | $941.39 | 24.82% | 55.26% |
| Oct 23, 2024 | Mohit Bansal | Wells Fargo | $1.05K | $962.34 | 9.11% | 38.74% |
| Sep 24, 2024 | Thomas Klee | Truist Financial | $1.20K | $1.09K | 9.89% | 58.56% |
| Sep 24, 2024 | David Risinger | Leerink Partners | $1.08K | $1.09K | -1.37% | 42.31% |
| Sep 24, 2024 | Brian Skorney | Robert W. Baird | $940.00 | $1.09K | -13.92% | 24.21% |
| Sep 24, 2024 | Salveen Richter | Goldman Sachs | $1.29K | $1.09K | 18.32% | 70.72% |
The latest Regeneron Pharmaceuticals stock forecast, released on Nov 01, 2024 by Evan David Seigerman from BMO Capital, set a price target of $1.19K, which represents a 41.06% increase from the stock price at the time of the forecast ($843.60), and a 57.24% increase from REGN last price ($756.81).
Regeneron Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 6 | 13 | 32 |
| Avg Price Target | $1.11K | $1.15K | $1.15K |
| Last Closing Price | $756.81 | $756.81 | $756.81 |
| Upside/Downside | 46.67% | 52.39% | 51.32% |
In the current month, the average price target of Regeneron Pharmaceuticals stock is $1.11K, according to 6 Wall Street analysts offering twelve months forecast. The average price target represents a 46.67% increase as opposed to Regeneron Pharmaceuticals's last price of $756.81. This month's average price target is down -3.76% compared to last quarter, and down -3.08% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 13, 2024 | Citigroup | - | Neutral | Initialise |
| Nov 01, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Oct 29, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 24, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Oct 23, 2024 | Susquehanna | Neutral | Neutral | Hold |
| Oct 23, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Oct 23, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 23, 2024 | Barclays | Overweight | Overweight | Hold |
| Oct 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 23, 2024 | Wells Fargo | Overweight | Overweight | Hold |
Regeneron Pharmaceuticals's last stock rating was published by Citigroup on Nov 13, 2024. The company Initialise its REGN rating from "null" to "Neutral".
Regeneron Pharmaceuticals Financial Forecast
Regeneron Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $3.43B | $3.36B | $3.16B | $3.16B | $3.41B | $2.94B | $2.86B | $2.97B | $4.95B | $3.45B | $5.14B | $2.53B | $2.42B | $2.29B | $1.95B | $1.83B | $2.17B | $2.05B | $1.93B | $1.71B | $1.51B | $1.32B |
| Avg Forecast | $3.99B | $3.89B | $3.79B | $3.56B | $3.75B | $3.67B | $3.38B | $3.23B | $3.29B | $3.23B | $3.02B | $3.00B | $3.12B | $2.92B | $2.79B | $2.69B | $4.56B | $2.75B | $3.96B | $2.50B | $2.42B | $2.08B | $1.73B | $1.76B | $2.11B | $1.99B | $1.80B | $1.77B | $1.41B | $1.38B |
| High Forecast | $4.31B | $4.20B | $4.10B | $3.73B | $4.09B | $3.68B | $3.38B | $3.23B | $3.43B | $3.38B | $3.26B | $3.24B | $3.37B | $2.92B | $2.79B | $2.69B | $4.56B | $2.75B | $3.96B | $2.50B | $2.42B | $2.08B | $1.73B | $1.76B | $2.11B | $1.99B | $1.80B | $1.77B | $1.69B | $1.66B |
| Low Forecast | $3.75B | $3.65B | $3.56B | $3.40B | $3.61B | $3.67B | $3.38B | $3.23B | $2.99B | $3.01B | $2.84B | $2.81B | $2.93B | $2.92B | $2.79B | $2.69B | $4.56B | $2.75B | $3.96B | $2.50B | $2.42B | $2.08B | $1.73B | $1.76B | $2.11B | $1.99B | $1.80B | $1.77B | $1.13B | $1.11B |
| # Analysts | 1 | 1 | 1 | 3 | 16 | 8 | 5 | 4 | 8 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | 1.04% | 1.04% | 1.04% | 1.05% | 1.09% | 1.01% | 1.02% | 1.10% | 1.09% | 1.26% | 1.30% | 1.01% | 1.00% | 1.10% | 1.13% | 1.04% | 1.03% | 1.03% | 1.07% | 0.97% | 1.07% | 0.95% |
Regeneron Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $3.23B, with a low forecast of $3.23B, and a high forecast of $3.23B. REGN's average Quarter revenue forecast represents a -6.09% decrease compared to the company's last Quarter revenue of $3.43B (Dec 23).
Regeneron Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 16 | 8 | 5 | 4 | 8 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | $972.90M | $1.11B | $1.02B | $1.03B | $1.37B | $1.62B | $1.17B | $1.18B | $2.59B | $1.90B | $3.84B | $1.33B | $1.30B | $1.08B | $987.40M | $730.80M | $950.80M | $829.20M | $284.80M | $604.80M | $628.20M | $477.90M |
| Avg Forecast | $1.71B | $1.66B | $1.62B | $1.52B | $1.61B | $1.57B | $1.45B | $1.17B | $1.41B | $1.38B | $1.29B | $1.06B | $2.39B | $1.25B | $1.19B | $963.12M | $1.95B | $1.17B | $1.69B | $1.20B | $1.03B | $889.44M | $737.33M | $674.77M | $899.97M | $848.52M | $770.55M | $717.58M | $581.98M | $499.77M |
| High Forecast | $1.84B | $1.80B | $1.75B | $1.59B | $1.75B | $1.57B | $1.45B | $1.40B | $1.46B | $1.44B | $1.39B | $1.27B | $2.87B | $1.25B | $1.19B | $1.16B | $1.95B | $1.17B | $1.69B | $1.44B | $1.03B | $889.44M | $737.33M | $809.72M | $899.97M | $848.52M | $770.55M | $861.09M | $698.38M | $599.72M |
| Low Forecast | $1.60B | $1.56B | $1.52B | $1.45B | $1.54B | $1.57B | $1.45B | $932.30M | $1.28B | $1.29B | $1.21B | $847.54M | $1.91B | $1.25B | $1.19B | $770.49M | $1.95B | $1.17B | $1.69B | $962.39M | $1.03B | $889.44M | $737.33M | $539.81M | $899.97M | $848.52M | $770.55M | $574.06M | $465.59M | $399.82M |
| Surprise % | - | - | - | - | - | - | - | - | 0.69% | 0.80% | 0.79% | 0.97% | 0.57% | 1.30% | 0.98% | 1.22% | 1.33% | 1.62% | 2.27% | 1.11% | 1.26% | 1.22% | 1.34% | 1.08% | 1.06% | 0.98% | 0.37% | 0.84% | 1.08% | 0.96% |
4 analysts predict REGN's average Quarter EBITDA for Mar 24 to be $1.17B, with a high of $1.40B and a low of $932.30M. This is 19.78% upper than Regeneron Pharmaceuticals's previous annual EBITDA (Dec 23) of $972.90M.
Regeneron Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 16 | 8 | 5 | 4 | 8 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 7 |
| Net Income | - | - | - | - | - | - | - | - | $1.16B | $1.01B | $968.40M | $817.80M | $1.20B | $1.32B | $852.10M | $973.50M | $2.23B | $1.63B | $3.10B | $1.12B | $1.15B | $842.10M | $897.30M | $624.60M | $792.00M | $669.60M | $193.10M | $461.10M | $477.98M | $248.93M |
| Avg Forecast | $1.36B | $1.50B | $1.44B | $1.27B | $1.29B | $1.36B | $1.23B | $987.37M | $1.25B | $1.24B | $1.14B | $897.61M | $2.06B | $1.13B | $994.55M | $816.01M | $2.35B | $1.19B | $2.05B | $1.00B | $966.97M | $802.38M | $682.36M | $576.71M | $799.77M | $738.72M | $625.97M | $547.08M | $442.82M | $260.32M |
| High Forecast | $1.50B | $1.65B | $1.59B | $1.39B | $1.54B | $1.37B | $1.23B | $1.18B | $1.41B | $1.39B | $1.26B | $1.08B | $2.47B | $1.13B | $994.55M | $979.21M | $2.35B | $1.19B | $2.05B | $1.21B | $966.97M | $802.38M | $682.36M | $692.05M | $799.77M | $738.72M | $625.97M | $656.50M | $531.38M | $312.38M |
| Low Forecast | $1.25B | $1.38B | $1.32B | $1.15B | $967.28M | $1.35B | $1.23B | $789.90M | $900.22M | $991.15M | $1.05B | $718.09M | $1.64B | $1.13B | $994.55M | $652.81M | $2.35B | $1.19B | $2.05B | $803.94M | $966.97M | $802.38M | $682.36M | $461.37M | $799.77M | $738.72M | $625.97M | $437.67M | $354.25M | $208.26M |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 0.81% | 0.85% | 0.91% | 0.58% | 1.17% | 0.86% | 1.19% | 0.95% | 1.37% | 1.52% | 1.11% | 1.19% | 1.05% | 1.31% | 1.08% | 0.99% | 0.91% | 0.31% | 0.84% | 1.08% | 0.96% |
Regeneron Pharmaceuticals's average Quarter net income forecast for Mar 24 is $987.37M, with a range of $789.90M to $1.18B. REGN's average Quarter net income forecast represents a -14.85% decrease compared to the company's last Quarter net income of $1.16B (Dec 23).
Regeneron Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 16 | 8 | 5 | 4 | 8 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 7 |
| SG&A | - | - | - | - | - | - | - | - | $737.70M | $640.50M | $652.00M | $601.10M | $660.50M | $529.10M | $476.30M | $450.00M | $559.60M | $445.00M | $414.70M | $405.60M | $303.50M | $326.90M | $348.30M | $367.30M | $586.80M | $419.90M | $417.30M | $410.80M | $330.77M | $296.85M |
| Avg Forecast | $702.35M | $684.97M | $667.69M | $627.22M | $660.64M | $646.55M | $595.30M | $456.41M | $579.61M | $568.67M | $531.89M | $414.92M | $515.93M | $512.93M | $491.65M | $377.20M | $802.74M | $483.18M | $697.29M | $365.49M | $425.34M | $366.30M | $303.66M | $339.14M | $370.64M | $349.45M | $317.34M | $487.40M | $306.44M | $310.43M |
| High Forecast | $757.96M | $739.20M | $720.55M | $655.65M | $719.75M | $647.90M | $595.30M | $547.69M | $602.73M | $594.27M | $574.01M | $497.90M | $619.12M | $512.93M | $491.65M | $452.64M | $802.74M | $483.18M | $697.29M | $438.59M | $425.34M | $366.30M | $303.66M | $406.97M | $370.64M | $349.45M | $317.34M | $584.88M | $367.72M | $372.51M |
| Low Forecast | $659.13M | $642.82M | $626.60M | $598.79M | $634.56M | $645.20M | $595.30M | $365.13M | $526.28M | $529.07M | $499.16M | $331.94M | $412.74M | $512.93M | $491.65M | $301.76M | $802.74M | $483.18M | $697.29M | $292.39M | $425.34M | $366.30M | $303.66M | $271.31M | $370.64M | $349.45M | $317.34M | $389.92M | $245.15M | $248.34M |
| Surprise % | - | - | - | - | - | - | - | - | 1.27% | 1.13% | 1.23% | 1.45% | 1.28% | 1.03% | 0.97% | 1.19% | 0.70% | 0.92% | 0.59% | 1.11% | 0.71% | 0.89% | 1.15% | 1.08% | 1.58% | 1.20% | 1.31% | 0.84% | 1.08% | 0.96% |
Regeneron Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $456.41M, based on 4 Wall Street analysts, with a range of $365.13M to $547.69M. The forecast indicates a -38.13% fall compared to REGN last annual SG&A of $737.70M (Dec 23).
Regeneron Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 16 | 8 | 5 | 4 | 8 | 20 | 10 | 10 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 15 | 7 |
| EPS | - | - | - | - | - | - | - | - | $10.88 | $9.48 | $9.05 | $7.64 | $11.19 | $12.31 | $7.90 | $9.12 | $20.99 | $15.37 | $29.51 | $10.58 | $10.90 | $7.98 | $8.19 | $5.69 | $7.25 | $6.12 | $1.77 | $4.23 | $4.44 | $2.36 |
| Avg Forecast | $11.73 | $12.91 | $12.39 | $10.94 | $11.11 | $11.69 | $10.62 | $10.17 | $10.73 | $10.68 | $9.85 | $9.52 | $10.25 | $9.76 | $8.62 | $9.72 | $20.40 | $10.35 | $17.72 | $8.68 | $8.38 | $6.95 | $5.91 | $6.06 | $6.93 | $6.40 | $5.42 | $5.48 | $4.03 | $3.20 |
| High Forecast | $12.94 | $14.24 | $13.67 | $11.93 | $13.23 | $11.77 | $10.62 | $10.17 | $12.12 | $11.95 | $10.86 | $10.50 | $11.30 | $9.76 | $8.62 | $9.72 | $20.40 | $10.35 | $17.72 | $8.68 | $8.38 | $6.95 | $5.91 | $6.06 | $6.93 | $6.40 | $5.42 | $5.48 | $4.84 | $3.84 |
| Low Forecast | $10.80 | $11.88 | $11.40 | $9.93 | $8.32 | $11.61 | $10.62 | $10.17 | $7.75 | $8.53 | $9.06 | $8.76 | $9.43 | $9.76 | $8.62 | $9.72 | $20.40 | $10.35 | $17.72 | $8.68 | $8.38 | $6.95 | $5.91 | $6.06 | $6.93 | $6.40 | $5.42 | $5.48 | $3.22 | $2.56 |
| Surprise % | - | - | - | - | - | - | - | - | 1.01% | 0.89% | 0.92% | 0.80% | 1.09% | 1.26% | 0.92% | 0.94% | 1.03% | 1.49% | 1.67% | 1.22% | 1.30% | 1.15% | 1.39% | 0.94% | 1.05% | 0.96% | 0.33% | 0.77% | 1.10% | 0.74% |
According to 4 Wall Street analysts, Regeneron Pharmaceuticals's projected average Quarter EPS for Mar 24 is $10.17, with a low estimate of $10.17 and a high estimate of $10.17. This represents a -6.52% decrease compared to REGN previous annual EPS of $10.88 (Dec 23).
Regeneron Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics | $13.97 | $115.90 | 729.63% | Buy |
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $18.57 | $45.38 | 144.37% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.75 | $106.93 | 138.95% | Buy |
| CRSP | CRISPR Therapeutics | $47.25 | $101.46 | 114.73% | Buy |
| SRPT | Sarepta Therapeutics | $104.54 | $169.06 | 61.72% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| NVO | Novo Nordisk | $101.74 | $158.00 | 55.30% | Buy |
| IONS | Ionis Pharmaceuticals | $34.34 | $51.68 | 50.50% | Buy |
| BGNE | BeiGene | $189.23 | $255.80 | 35.18% | Buy |
| REGN | Regeneron Pharmaceuticals | $756.81 | $995.63 | 31.56% | Buy |
| PTCT | PTC Therapeutics | $39.23 | $46.50 | 18.53% | Hold |
| KRYS | Krystal Biotech | $170.74 | $191.00 | 11.87% | Buy |
| INCY | Incyte | $75.87 | $84.56 | 11.45% | Buy |
| MDGL | Madrigal Pharmaceuticals | $288.58 | $315.75 | 9.42% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| UTHR | United Therapeutics | $363.25 | $358.20 | -1.39% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |